<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02200757</url>
  </required_header>
  <id_info>
    <org_study_id>ALDOXORUBICIN-P2-SCLC-01</org_study_id>
    <nct_id>NCT02200757</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Aldoxorubicin Compared to Topotecan in Subjects With Metastatic Small Cell Lung Cancer</brief_title>
  <official_title>A Multicenter, Randomized, Open-Label Phase 2b Study to Investigate the Efficacy and Safety of Aldoxorubicin Compared to Topotecan in Subjects With Metastatic Small Cell Lung Cancer Who Either Relapsed or Were Refractory to Prior Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CytRx</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CytRx</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of aldoxorubicin compared to
      topotecan in subjects with metastatic small cell lung cancer.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>September 2014</start_date>
  <completion_date type="Anticipated">July 2017</completion_date>
  <primary_completion_date type="Anticipated">September 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-Free Survival (PFS)</measure>
    <time_frame>24 months</time_frame>
    <description>PFS is defined as the time from the date of randomization to first documentation of objective tumor progression or to death due to any cause in the absence of previous documentation of objective tumor progression.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>36 months</time_frame>
    <description>Overall survival is defined as the time from randomization to date of death. In the absence of confirmation of death, survival time will be censored at the last date the subject is known to be alive.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety Measures</measure>
    <time_frame>24 months</time_frame>
    <description>The safety of aldoxorubicin compared to topotecan in this population assessed by the frequency and severity of adverse events (AEs), abnormal findings on physical examination, laboratory tests, vital signs, echocardiogram (ECHO) evaluations, electrocardiogram (ECG) results, and weight, as well as disease control rate and tumor response.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">132</enrollment>
  <condition>Metastatic Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Aldoxorubicin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Topotecan</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aldoxorubicin</intervention_name>
    <description>230 mg/m2 (170 mg/m2 doxorubicin equivalent) intravenously on Day 1 of each 21-day cycle. Number of cycles: until tumor progression or unacceptable toxicity occurs.</description>
    <arm_group_label>Aldoxorubicin</arm_group_label>
    <other_name>INNO-206</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Topotecan</intervention_name>
    <description>1.5 mg/m2/day intravenously for 5 consecutive days on Day 1 of each 21-day cycle OR 4 mg/m2 intravenously on Days 1, 8 and 15 of each 28-day cycle. Number of cycles: until tumor progression or unacceptable toxicity occurs</description>
    <arm_group_label>Topotecan</arm_group_label>
    <other_name>Hycamtin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age ≥18 years male or female.

          2. Histological confirmation of SCLC.

          3. Relapsed or refractory to no more than 1 course of a systemic therapy regimen and is
             incurable by either surgery or radiation.

          4. Capable of providing informed consent and complying with trial procedures.

          5. ECOG PS 0-2.

          6. Life expectancy &gt;8 weeks.

          7. Measurable tumor lesions according to RECIST 1.1 criteria.[22]

          8. Women must not be able to become pregnant (e.g. post-menopausal for at least 1 year,
             surgically sterile, or practicing adequate birth control methods) for the duration of
             the study. (Adequate contraception includes: oral contraception, implanted
             contraception, intrauterine device implanted for at least 3 months, or barrier method
             in conjunction with spermicide.)

          9. Males and their female partner(s) of child-bearing potential must use 2 forms of
             effective contraception (see Inclusion 8 plus condom or vasectomy for males) from the
             last menstrual period of the female partner during the study treatment and for 6
             months after the final dose of study treatment.

         10. Women of child bearing potential must have a negative serum or urine pregnancy test at
             the Screening Visit and be non-lactating.

         11. Accessibility to the site that ensures the subject will be able to keep all
             study-related appointments.

        Exclusion Criteria:

          1. Prior exposure to &gt;375 mg/m2 of doxorubicin or liposomal doxorubicin.

          2. Prior treatment with topotecan.

          3. Palliative surgery and/or radiation treatment &lt; 21 days prior to date of
             randomization.

          4. Exposure to any investigational agent within 30 days of date of randomization.

          5. Exposure to any systemic chemotherapy within 21 days of date of randomization.

          6. Active (symptomatic) central nervous system (CNS) metastasis.

          7. History of other malignancies except cured basal cell carcinoma, cutaneous squamous
             cell carcinoma, melanoma in situ, superficial bladder cancer or carcinoma in situ of
             the cervix unless documented free of cancer for ≥3 years.

          8. Laboratory values: Screening serum creatinine &gt;1.5×upper limit of normal (ULN),
             alanine aminotransferase (ALT) &gt;3×ULN or &gt;5×ULN if liver metastases are present, total
             bilirubin &gt;2×ULN, absolute neutrophil count (ANC) &lt;1,500/mm3, platelet concentration
             &lt;100,000/mm3, hemoglobin &lt;9 g/dL, albumin &lt;2 gm/dL.

          9. Anion gap &gt; 16 meq/L or arterial blood pH &lt; 7.30.

         10. Clinically evident congestive heart failure (CHF) &gt; class II of the New York Heart
             Association (NYHA) guidelines (Appendix D).

         11. Current, serious, clinically significant cardiac arrhythmias, defined as the existence
             of an absolute arrhythmia or ventricular arrhythmias classified as Lown III, IV or V
             (Appendix F).

         12. Baseline QTc &gt;470 msec measured by Fridericia's formula (QTcF) and/or previous history
             of QT prolongation while taking other medications. Concomitant use of medications
             associated with a high incidence of QT prolongation is not allowed.

         13. History or signs of active coronary artery disease with angina pectoris within the
             last 6 months.

         14. Serious myocardial dysfunction defined by ECHO as absolute left ventricular ejection
             fraction (LVEF) below the institution's lower limit of predicted normal.

         15. Known history of HIV infection.

         16. Active, clinically significant serious infection requiring treatment with antibiotics,
             anti-virals or anti-fungals.

         17. Treatment with p-glycoprotein inhibitors such as cyclosporine A, elacridar,
             ketoconazole, ritonavir, saquinavir.

         18. Major surgery within 30 days prior to date of randomization.

         19. Substance abuse or any condition that might interfere with the subject's participation
             in the study or in the evaluation of the study results.

         20. Any condition that is unstable and could jeopardize the subject's participation in the
             study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Cedars-Sinai Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cynthia Martin</last_name>
      <phone>910-423-2276</phone>
      <email>cynthia.martin@cshs.org</email>
    </contact>
    <investigator>
      <last_name>Alain Mita, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>City of Hope Medical Group</name>
      <address>
        <city>Pasadena</city>
        <state>California</state>
        <zip>91030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>New Patient Services</last_name>
      <phone>626-256-4673</phone>
    </contact>
    <investigator>
      <last_name>Marianna Koczywas, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Colorado Cancer Center</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Lynn Cancer Institute</name>
      <address>
        <city>Boca Raton</city>
        <state>Florida</state>
        <zip>33486</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Cancer Specialists of North Florida-Fleming Island</name>
      <address>
        <city>Fleming Island</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melissa Rammage</last_name>
      <phone>904-538-4488</phone>
      <email>research@CSNF.US</email>
    </contact>
    <investigator>
      <last_name>Augusto Villegas, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hematoloy Oncology Associates</name>
      <address>
        <city>Port St. Lucie</city>
        <state>Florida</state>
        <zip>34982</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Northwest Georgia Oncology Centers, P.C.</name>
      <address>
        <city>Marietta</city>
        <state>Georgia</state>
        <zip>30060</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melissa Lee</last_name>
      <phone>770-281-5131</phone>
      <email>mlee@ngoc.com</email>
    </contact>
    <investigator>
      <last_name>Robert Hermann, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>James Graham Brown Cancer Center</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Schoenbachler</last_name>
      <phone>502-562-3429</phone>
      <email>jmgoyn01@louisville.edu</email>
    </contact>
    <investigator>
      <last_name>Goetz Kloecker, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>West Jefferson Medical Center, Cancer Center</name>
      <address>
        <city>Marrero</city>
        <state>Louisiana</state>
        <zip>70072</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Bay Hematology Oncology</name>
      <address>
        <city>Easton</city>
        <state>Maryland</state>
        <zip>21601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine, Department of Internal Medicine</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Montefiore Medical Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Oncology Hermatology Care, Inc.</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patient Hotline</last_name>
      <phone>877-691-7274</phone>
      <email>askSarah@scresearch.net</email>
    </contact>
    <investigator>
      <last_name>David Waterhouse, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northwest CCOP Kaiser Permanente</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97227</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rhonda Stephenson</last_name>
      <phone>503-331-6537</phone>
      <email>rhonda.stephenson@kpchr.org</email>
    </contact>
    <investigator>
      <last_name>Abdul Hai Mansoor, M.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Penn State Hershey Cancer Institute</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Heather Austin</last_name>
      <phone>772-408-5158</phone>
      <email>haustin@hemoncfl.com</email>
    </contact>
    <investigator>
      <last_name>Chandra Belani, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tennessee Oncology</name>
      <address>
        <city>Cattanooga</city>
        <state>Tennessee</state>
        <zip>37404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hotline</last_name>
      <phone>877-691-7274</phone>
      <email>askSarah@scresearch.net</email>
    </contact>
    <investigator>
      <last_name>Davey Daniel, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tennessee Cancer Specialists</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37909</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susie Owen</last_name>
      <phone>865-934-2672</phone>
      <email>sowenby@biomed-research.com</email>
    </contact>
    <investigator>
      <last_name>Russel DeVore, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daphne Hubbard</last_name>
      <phone>615-524-4032</phone>
      <email>daphne.hubbard@scresearch.net</email>
    </contact>
    <investigator>
      <last_name>Ray Page, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Koranyi National Institute of TBC and Pulmonologyhhy</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katalin Udud</last_name>
      <phone>+36 (1) 391 3233</phone>
      <email>katiudud@freemail.hu</email>
    </contact>
    <investigator>
      <last_name>Katalin Udud, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Koranyi National Institute of TBC and Pulmonology</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erzsebet Juhasz</last_name>
      <phone>+36 (1) 391 3277</phone>
      <email>juhasz@koranyi.hu</email>
    </contact>
    <investigator>
      <last_name>Ildiko Horvath, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Debrecen, Medical and Health Science Center, Department of Pulmonology</name>
      <address>
        <city>Debrecen</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Szilasi</last_name>
      <phone>+36 (52) 414 222</phone>
      <email>mszilasi@dote.hu</email>
    </contact>
    <investigator>
      <last_name>Maria Szilasi, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Szabolcs-Szatmar-Bereg County Hospitals and University Teaching Hospital, Department of Pulmonology</name>
      <address>
        <city>Nyiregyhaza</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter Szabo</last_name>
      <phone>+36 (42) 403 266</phone>
      <email>dr.szabo.peter@josa.hu</email>
    </contact>
    <investigator>
      <last_name>Peter Szabo, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical Center of the University of Pecs, 1st Department of Internal Medicine</name>
      <address>
        <city>Pecs</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Veronika Sarosi</last_name>
      <email>sarosi.veronika@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Veronika Sarosi, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hetenyi Geza Hospital</name>
      <address>
        <city>Szolnok, Jasz-Nagykun-Szolnok</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tibor Csoszi</last_name>
      <phone>+36 (56) 503 603</phone>
      <email>dr.cstibor@freemail.hu</email>
    </contact>
    <investigator>
      <last_name>Tibor Csoszi, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario de Alicante</name>
      <address>
        <city>Alicante</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bartomeu Massuti</last_name>
      <phone>34 965 933 513</phone>
      <email>bmassutis@seom.org</email>
    </contact>
    <investigator>
      <last_name>Bartomeu Massuti, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic i Provincial de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Noemi Reguart</last_name>
      <phone>0034 93 227 54 02 ext 2811</phone>
      <email>NREGUART@clinic.ub.es</email>
    </contact>
    <investigator>
      <last_name>Noemi Reguart, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Quiron-Dexeus (IOR)</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rafael Rosell</last_name>
      <phone>34 93 546 0135</phone>
      <email>rrosell@iconcologia.net</email>
    </contact>
    <investigator>
      <last_name>Rafael Rosell, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alejandro Navarro</last_name>
      <phone>+34 (93) 274 6085</phone>
      <email>alnavarro@vhebron.net</email>
    </contact>
    <investigator>
      <last_name>Alejandro Navarro, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Lucus Augusti</name>
      <address>
        <city>Lugo</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Natlia Fernandez</last_name>
      <phone>34 982 296459</phone>
      <email>Natalia.fernandez.nunez@sergas.es</email>
    </contact>
    <investigator>
      <last_name>Natlia Fernandez, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>General University Hospital Gregorio Maranon</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ramon Garcia Gomez</last_name>
      <phone>+34 (91) 426 9393</phone>
      <email>ramon.garcia@salud.madrid.org</email>
    </contact>
    <investigator>
      <last_name>Ramon Garcia Gomez, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Puerta de Hierro</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mariano Provencio Pulla</last_name>
      <phone>+34 (91) 1917418</phone>
      <email>mprovencio.ensayosclinicos@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Mariano Provencio Pulla, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Foundation Jimenez Diaz</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Manuel Domine Gomez</last_name>
      <phone>+34 (91) 549 4908</phone>
      <email>mdomine@fjd.es</email>
    </contact>
    <investigator>
      <last_name>Manuel Domine Gomez, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital La Paz</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Javier De Castro</last_name>
      <phone>+34 (91) 727 7516</phone>
      <email>jcastro.hulp@salud.madrid.org</email>
    </contact>
    <investigator>
      <last_name>Javier De Castro, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Regional Universitario</name>
      <address>
        <city>Malaga</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vanesa Gutierrez</last_name>
      <phone>34 951 291 425</phone>
      <email>vanesa_gutierrez78@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Vanesa Gutierrez, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Virgen de Valme</name>
      <address>
        <city>Sevilla</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Reyes Bernabe Caro</last_name>
      <phone>34 95 501 9273</phone>
      <email>reyesbernab@yahoo.es</email>
    </contact>
    <investigator>
      <last_name>Reyes Bemabe Caro, M.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Xeral</name>
      <address>
        <city>Vigo</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martin Lazaro</last_name>
      <phone>34 986219 766</phone>
      <email>Martin.Lazaro.Quintela@sergas.es</email>
    </contact>
    <investigator>
      <last_name>Martin Lazaro, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Hungary</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 23, 2014</study_first_submitted>
  <study_first_submitted_qc>July 24, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 25, 2014</study_first_posted>
  <last_update_submitted>August 17, 2016</last_update_submitted>
  <last_update_submitted_qc>August 17, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 18, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Small Cell Lung Carcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Topotecan</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

